• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Delcath Systems Inc. (Amendment)

    5/17/24 12:48:32 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email
    SC 13D/A 1 rosalind_dcth_13da11_may.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D/A

    (Amendment No. 10)

    (Rule 13d-101)

    Under the Securities Exchange Act of 1934

    Delcath Systems, Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    24661P807

    (CUSIP Number)

    566 Queensbury Avenue, Queensbury, New York 12804

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    April 18, 2024

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

     

     

     

     

     

    CUSIP No. 24661P807

     

    13D/A

     

    Page 2 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)


    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)   ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
    0

     

    8.

     

    SHARED VOTING POWER
     
    2,763,468 shares of Common Stock

    95,692 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (see Item 5) 1

    2,332,256 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (see Item 5)

     

    9.

     

    SOLE DISPOSITIVE POWER
      0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    2,763,468 shares of Common Stock

    95,692 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (See Item 5)   

    2,332,256 shares of Common Stock issuable upon exercise of warrants (See Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


    2,763,468 shares of Common Stock

    95,692 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (See Item 5)   

    2,332,256 shares of Common Stock issuable upon exercise of warrants (See Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     


    1 As more fully described in Item 5, the shares of Preferred Stock and Warrants are subject to a 9.99% blocker, and the percentage set forth in row (13) gives effect to such blockers. However, as more fully described in Item 5, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).


      

    CUSIP No. 24661P807

     

    13D/A

     

    Page 3 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    82,197 shares of Common Stock

    47,846 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

     

    8.

     

    SHARED VOTING POWER

    2,650,389 shares of Common Stock
    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (See Item 5) 1

    2,332,256 shares of Common Stock issuable upon exercise of warrants (See Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    82,197 shares of Common Stock

    47,846 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    2,650,389 shares of Common Stock

    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (See Item 5) 1

    2,332,256 shares of Common Stock issuable upon exercise of warrants (See Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)   ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     


      

    CUSIP No. 24661P807

     

    13D/A

     

    Page 4 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gil Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
     
    30,882 shares of Common Stock

    47,846 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

     

    8.

     

    SHARED VOTING POWER

    2,650,389 shares of Common Stock

    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (See Item 5) 1

    2,332,256 shares of Common Stock issuable upon exercise of warrants (See Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    30,882 shares of Common Stock

    47,846 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    2,650,389 shares of Common Stock
    1,418,909 shares of Common Stock issuable upon conversion of 11,986 preferred stock (See Item 5) 1

    2,332,256 shares of Common Stock issuable upon exercise of warrants (See Item 5)

    230,458 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     


     

     

     

     

     

     

    CUSIP No. 24661P807

     

    13D/A

     

    Page 5 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
    0

     

    8.

     

    SHARED VOTING POWER
     
    1,565,844 shares of Common Stock

    701,500 shares of Common Stock issuable upon conversion of 8,215 preferred stock (see Item 5)1

    603,994 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    115,229 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    1,565,844 shares of Common Stock

    701,500 shares of Common Stock issuable upon conversion of 8,215 preferred stock (see Item 5)1

    603,994 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    115,229 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,565,844 shares of Common Stock

    701,500 shares of Common Stock issuable upon conversion of 8,215 preferred stock (see Item 5) 1

    603,994 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    115,229 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     


     

     

     

     

     

     

     

    CUSIP No. 24661P807

     

    13D/A

     

    Page 6 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Opportunities Fund I L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
    0

     

    8.

     

    SHARED VOTING POWER
     
    1,084,545 shares of Common Stock

    717,409 shares of Common Stock issuable upon conversion of 7,846 preferred stock (see Item 5)1

    1,728,262 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    115,229 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    1,084,545 shares of Common Stock

    717,409 shares of Common Stock issuable upon conversion of 7,846 preferred stock (see Item 5)1

    1,728,262 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    115,229 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,084,545 shares of Common Stock

    717,409 shares of Common Stock issuable upon conversion of 7,846 preferred stock (see Item 5) 1

    1,728,262 shares of Common Stock issuable upon exercise of warrants (see Item 5)

    115,229 shares of Common Stock issuable upon conversion of convertible debt (See Item 5)

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     


     

     

     

     

     

     

     

    CUSIP No. 24661P807

     

    13D/A

     

    Page 7 of 9 Pages

     

     

     

     

     

    The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”). Rosalind Advisors, Inc., Rosalind Opportunities Fund I L.P. (“ROFI”), and Rosalind Master Fund L.P. (“RMF”) previously jointly filed a statement on Schedule 13G pursuant to Rule 13d-1(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result of a change in purpose, the Reporting Persons (as hereinafter defined) transitioned to a Schedule 13D as of March 9, 2020.

    Item 1.  Security and Issuer.

     

    (a)

    This statement relates to the Preferred Stock (the “Shares”) of Delcath Systems, Inc., a Delaware corporation (the "Company").

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices:
    566 Queensbury Avenue

    Queensbury, New York 12804

     

     

     

     

    Item 2.  Identity and Background.

     

    (a)

    This statement is filed by:

    (i)Rosalind Advisors, Inc. (“Advisor” to ROFI & RMF) 

    (ii)Steven Salamon (“President” and portfolio manager of the Advisor) 

    (iii)Gil Aharon (“Secretary” and portfolio manager of the Advisor) 

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 7. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence

    Rosalind Advisors, Inc.

    15 Wellesley Street West

    Suite 326,

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Steven Salamon

    15 Wellesley Street West

    Suite 326,

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gil Aharon

    15 Wellesley Street West

    Suite 326,

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

     


     

     

     

     

     

     

    CUSIP No. 24661P807

     

    13D/A

     

    Page 8 of 9 Pages

     

     

    (c)

    The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments. The principal occupation of Mr. Salamon is serving as the Portfolio Manager and President of Rosalind Advisors, Inc., which advises ROFI & RMF.

     

     

     

     

    (d)

    No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

     

     

     

    (e)

    No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

     

    (f)

    Mr. Salamon is a citizen of Canada, resident in Ontario

     

    Item 4.  Purpose of Transaction

     Item 4 is hereby amended and supplemented as follows:

    On May 6, 2020, pursuant to the terms of the Board Appointment Agreement, the Board of Directors of the Issuer (the “Board”) increased the number of directors constituting the Board to eight members and elected Steven Salamon and Gilad Aharon as independent directors of the Issuer to fill the vacancies created by the increase in the number of directors. Mr. Salamon was elected to serve as a Class III director with a term scheduled to expire at the 2024 Annual Meeting of Stockholders and Dr. Aharon was elected to serve as a Class I director with a term scheduled to expire at the 2025 Annual Meeting of Stockholders.

    Item 5.  Interest in Securities of the Issuer.

     Amount beneficially owned:

    The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based on 27,785,803 shares of Common Stock issued and outstanding as of May 09, 2024, as represented in the Company’s Form 10-Q filed with the Securities and Exchange Commission on May 14, 2024, and assumes the exercise of the Company's reported warrants (the "Reported Warrants") and the conversion of the Company’s reported preferred stock (the “Reported Preferred Stock”), subject to the Blockers (as defined below).

    Pursuant to the terms of (i) the certificate of designations containing the terms of the Reported Preferred Stock, the Reporting Persons cannot convert the Reported Preferred Stock to the extent the Reporting Persons would beneficially own, after any such conversion, more than 9.99% of the outstanding shares of Common Stock (the "Preferred Stock Blockers") and (ii) the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Warrant Blockers" and collectively with the Preferred Stock Blockers, the "Blockers"), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blockers.  Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Preferred Stock or any of the Reported Warrants due to the Blockers.

    Rosalind Advisors, Inc. is the investment advisor to ROFI and RMF and may be deemed to be the beneficial owner of shares held by ROFI and RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares of Preferred Stock held, and underlying the Reported Warrants (subject to the Warrant Blockers) held by, RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of any such shares.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

     

     

     

     

    Item 7.  Material to Be Filed as Exhibits.

     

     

     

     

     

    A Joint Filing Agreement by and among Rosalind Advisors, Inc. Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. and Steven Salamon, was originally filed on March 27, 2020 as an Exhibit.


     

    CUSIP No. 24661P807

     

    13D/A

     

    Page 9 of 9 Pages

     

     

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    ROSALIND

     

    Steven Salamon

    Signature

     

    Steven Salamon/President, Rosalind Advisors, Inc.

    Name/Title

     

    16/05/2024

    Date

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13D/A with respect to the beneficial ownership of shares of Common Stock of Delcath Systems, Inc. is filed jointly on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    Steven Salamon

    By: _____________________________

    Name: Steven Salamon

     

     

    Get the next $DCTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025 at The Depot Renaissance Hotel in Minneapolis, MN. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PH

      5/15/25 4:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025. The grants resulted in the right to purchase 111,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The options were granted on April 30, 2025, the date the Compensation Committee approved the stock option included within the equi

      5/9/25 5:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aharon Gil exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 1:00:03 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Salamon Steven A J exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:36:53 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Rosalind Advisors, Inc. exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:15:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      1/23/24 4:36:46 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

      SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 7:02:01 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Delcath with a new price target

      Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

      6/28/24 8:18:39 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Delcath with a new price target

      Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:58:22 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity resumed coverage on Delcath with a new price target

      Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

      7/26/22 9:10:21 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aharon Gil bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 3% to 1,069,710 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 8:00:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Salamon Steven A J bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 2% to 1,121,025 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 7:44:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Vukovic Vojo bought $120,000 worth of shares (40,000 units at $3.00), increasing direct ownership by 67% to 100,000 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      12/14/23 4:20:16 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Delcath Systems Inc.

      10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 9:25:44 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 7:42:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Delcath Systems Inc.

      DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      4/1/25 8:58:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Financials

    Live finance-specific insights

    See more
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Host First Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

      4/24/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively Gross mar

      3/6/25 8:00:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

      NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

      3/18/24 5:20:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care